Description | Value | Reference | ||
---|---|---|---|---|
 | Base-case estimate | Range for sensitivity analysis | (reference for range) | |
 |  | Low | High |  |
Costs (2012 USD) | ||||
Disease costs | ||||
Medical costs | Â | Â | Â | Â |
Mild malaria | Â | Â | Â | Â |
Public health systems | 0.51 | 0.26 | 0.77 | [27] (±50%) |
Households | 0.50 | 0.21 | 1.00 | [28] (±50%) |
Severe malaria (CM, SMA) | Â | Â | Â | Â |
Public health systems | 12.76 | 6.38 | 19.14 | [27] (±50%) |
Households | 0.50 | 0.21 | 1.00 | [28] (±50%) |
Non-medical costs | Â | Â | Â | Â |
(Productivity costs) | ||||
Mild, CM, SMA | Â | Â | Â | Â |
Adults | 2.52 | 1.26 | 3.78 | |
Children | 1.11 | 0.56 | 1.67 | |
Death | 4.76 | 2.38 | 7.14 | [16] (±50%) |
Vaccine costs | ||||
Price per dose | 7 | 1 | 15 | |
Administration per dose | 0.37 | 0.19 | 0.57 | [30] (±50%) |
Total costs for 3 doses | 22.11 | 3.57 | 46.71 | Â |
LLINs costs | ||||
LLIN per two persons | 3.16 | 2.23 | 5.23 | |
DALY-related parameters | ||||
Life expectancy | 47.1Â years | Â | Â | [23] |
Disability weights | Â | Â | Â | [33] |
Mild malaria | 0.191 | 0.172 | 0.211 | Â |
CM | 0.471 | 0.443 | 0.471 | Â |
SMA | 0.471 | 0.191 | 0.471 | Â |
Death | 1 | Â | Â | Â |
Effectiveness parameters | ||||
Vaccine protection efficacy | ||||
Mild Malaria | 0.539 | 0.496 | 0.578 | [12] (95% CI) |
Severe Malaria (CM, SMA) | 0.313 | 0.142 | 0.448 | [12] (95% CI) |
Death | 0.2 | 0.15 | 0.25 | [19] (±25%) |
Duration of protection | 45Â months | 11Â months | 10Â years | [14] |
Vaccine coverage | 0.85 | 0.64 | 0.99 | |
LLIN protection efficacy | ||||
Mild Malaria | 0.5 | 0.43 | 0.62 | [36] (Min, Max) |
Severe Malaria (CM, SMA) | 0.45 | 0.2 | 0.63 | [36] (95% CI) |
Death | 0.17 | 0.1 | 0.24 | [36] (95% CI) |
Duration of protection | 3Â years | 3Â years | 5Â years | [37] (Min, Max) |
LLIN coverage | 80% | 55.4% | 80% | [7] (Baseline (2010) - Target (2015)) |
LLIN use | 88% | 87% | 90% | [38] (95% CI) |
Discount rate% | 3% | 0% | 6% | [39] |